Can a New Prostate MRI Software Have an Impact?
Emphasizing restriction spectrum imaging (RSI), the recently launched prostate MRI software OnQ Prostate may enhance PI-RADS assessments and workflow efficiency.
In order to enhance the detection of clinically significant prostate cancer (csPCa), Cortechs.ai has launched OnQ Prostate, a post-processing software that may bolster prostate MRI interpretation through a proprietary diffusion-weighted imaging called restriction spectrum imaging (RSI).
Originally developed for brain cancer imaging, RSI reportedly increases the detection of aggressive cancer cells, according to Cortechs.ai. The company noted that research with the FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging.
The FDA-cleared OnQ Prostate software has demonstrated improved in vivo characterization and localization of csPCa on diffusion MRI imaging, according to Cortechs.ai, the developer of the software. (Image courtesy of Cortechs.ai .)
In addition to improved accuracy with PI-RADS assessments, Cortechs.ai said the OnQ Prostate software offers a versatility that can enhance workflows with radiologists and referring providers by facilitating patient selection for biopsy procedures, treatment planning and post-treatment assessment.
“This announcement is an important step in increasing the awareness and accessibility of OnQ Prostate beyond its earliest adopters so that more physicians and patients can benefit from this technology,” says Brittany Hunt, the head of prostate business development at Cortechs.ai.
Recent Videos
Related Content
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Article
Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
Expanded FDA Approval Allows Use of Pluvicto Prior to Chemotherapy in Patients with mCRPC
March 28th 2025Article
Recent research demonstrated a 59 percent reduced risk of progression or death with the radioligand therapy Pluvicto in comparison to a change of androgen receptor pathway inhibitor (ARPI) for patients with metastatic castration-resistant prostate cancer (mCRPC).
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Article
Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
